Literature DB >> 19805389

Reversal of long-term dendritic spine alterations in Alzheimer disease models.

Donna L Smith1, Julio Pozueta, Bing Gong, Ottavio Arancio, Michael Shelanski.   

Abstract

Synapse loss is strongly correlated with cognitive impairment in Alzheimer's disease (AD). We have previously reported the loss of dendritic spines and the presence of dystrophic neurites in both the hippocampi of transgenic mice overexpressing amyloid precursor protein (APP) and in the human brain affected with AD. In the studies reported here we have asked whether the acute alterations in dendritic spines induced by Abeta, as well as the chronic loss of spine density seen in hAPP transgenic mice, are reversible by treatments that restore the cAMP/PKA/CREB signaling pathway or proteasome function to control levels. The results show that both rolipram and TAT-HA-Uch-L1 restore spine density to near control conditions, even in elderly mice. The results suggest that changes in dendritic structure and function that occur after Abeta elevation are reversible even after long periods of time, and that one could envision therapeutic approaches to AD based on this restoration that could work independently of therapies aimed at lowering Abeta levels in the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805389      PMCID: PMC2743726          DOI: 10.1073/pnas.0908706106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Inactivity produces increases in neurotransmitter release and synapse size.

Authors:  V N Murthy; T Schikorski; C F Stevens; Y Zhu
Journal:  Neuron       Date:  2001-11-20       Impact factor: 17.173

2.  Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons.

Authors:  M Matsuzaki; G C Ellis-Davies; T Nemoto; Y Miyashita; M Iino; H Kasai
Journal:  Nat Neurosci       Date:  2001-11       Impact factor: 24.884

Review 3.  Structure and function of dendritic spines.

Authors:  Esther A Nimchinsky; Bernardo L Sabatini; Karel Svoboda
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

4.  Multicolor "DiOlistic" labeling of the nervous system using lipophilic dye combinations.

Authors:  W B Gan; J Grutzendler; W T Wong; R O Wong; J W Lichtman
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

5.  Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats.

Authors:  A Itoh; T Akaike; M Sokabe; A Nitta; R Iida; A Olariu; K Yamada; T Nabeshima
Journal:  Eur J Pharmacol       Date:  1999-10-15       Impact factor: 4.432

6.  Critical periods for experience-dependent synaptic scaling in visual cortex.

Authors:  Niraj S Desai; Robert H Cudmore; Sacha B Nelson; Gina G Turrigiano
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

7.  Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo.

Authors:  D B Freir; C Holscher; C E Herron
Journal:  J Neurophysiol       Date:  2001-02       Impact factor: 2.714

8.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.

Authors:  Ganesh M Shankar; Brenda L Bloodgood; Matthew Townsend; Dominic M Walsh; Dennis J Selkoe; Bernardo L Sabatini
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

View more
  104 in total

Review 1.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

2.  Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Keely M Murphy; Liping Meng; Janitza Montalvo-Ortiz; Ziling Zeng; Benedict J Kolber; Shanshan Zhang; Louis J Muglia; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease.

Authors:  Olivier Thibault; Tristano Pancani; Philip W Landfield; Christopher M Norris
Journal:  Biochim Biophys Acta       Date:  2012-01-10

4.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

5.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

6.  Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Authors:  Sung-Jun Park; Faiyaz Ahmad; Andrew Philp; Keith Baar; Tishan Williams; Haibin Luo; Hengming Ke; Holger Rehmann; Ronald Taussig; Alexandra L Brown; Myung K Kim; Michael A Beaven; Alex B Burgin; Vincent Manganiello; Jay H Chung
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

7.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

Review 8.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 9.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 10.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.